ACE2 mimetic antibody potently neutralizes all SARS-CoV-2 variants and fully protects in XBB.1.5 challenged monkeys
暂无分享,去创建一个
A. Farina | D. Trono | J. Neyts | V. Contreras | P. Leyssen | F. Pojer | P. Turelli | R. Le Grand | R. Marlin | N. Dereuddre-Bosquet | Francis Relouzat | C. Fenwick | R. Abdelnabi | C. Raclot | C. Hérate | K. Lau | Line Esteves-Leuenberger | Jérémy Campos | Flurin Fiscalini | C. Foo | Giuseppe Pantaleo | Henning Stahlberg | Vanessa Genet | Y. Duhoo | Yves Lévy | Laurent Perez | Myriam Lamrayah | Julien Cesborn | Kyllian Lheureux
[1] P. Klenerman,et al. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy , 2023, Nature communications.
[2] Jiahua He,et al. Improvement of cryo-EM maps by simultaneous local and non-local deep learning , 2023, Nature communications.
[3] Michael I. Jordan,et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. , 2023, JAMA.
[4] L. Käll,et al. Automated model building and protein identification in cryo-EM maps , 2023, bioRxiv.
[5] J. Zahradník,et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants , 2023, Nature communications.
[6] B. Pulendran,et al. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine , 2023, Science Translational Medicine.
[7] Qian Wang,et al. Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking , 2023, bioRxiv.
[8] Lisa E. Gralinski,et al. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease , 2023, Immunity.
[9] S. Bhatt,et al. Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US , 2023, JAMA network open.
[10] Klaus N. Lovendahl,et al. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection , 2022, bioRxiv.
[11] A. Walls,et al. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains , 2022, bioRxiv.
[12] M. Nussenzweig,et al. Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape , 2022, bioRxiv.
[13] G. Pantaleo,et al. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys , 2022, Nature Microbiology.
[14] Shinji Watanabe,et al. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys , 2022, Vaccine.
[15] R. Gottardo,et al. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients , 2022, JAMA oncology.
[16] J. Dye,et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans , 2022, Science Translational Medicine.
[17] J. Doudna,et al. Rapid assessment of SARS-CoV-2–evolved variants using virus-like particles , 2021, bioRxiv.
[18] G. Pantaleo,et al. A highly potent antibody effective against SARS-CoV-2 variants of concern , 2021, Cell Reports.
[19] J. Dye,et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants , 2021, bioRxiv.
[20] Samuel J. Hinshaw,et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates , 2021, Science Translational Medicine.
[21] M. V. van Breemen,et al. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models , 2021, Research square.
[22] Lisa E. Gralinski,et al. An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 , 2020, bioRxiv.
[23] P. Maes,et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters , 2020, Nature Communications.
[24] G. Pantaleo,et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies , 2020, Journal of Virology.
[25] A. H. Mohammed,et al. The Risk and Impact of COVID-19 Pandemic on Immunosuppressed Patients: Cancer, HIV, and Solid Organ Transplant Recipients. , 2020, AIDS reviews.
[26] B. Weynand,et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity , 2020, Proceedings of the National Academy of Sciences.
[27] Conrad C. Huang,et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers , 2020, Protein science : a publication of the Protein Society.
[28] X. de Lamballerie,et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates , 2020, Nature.
[29] J. Matthijnssens,et al. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate , 2020, Nature.
[30] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[31] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[32] Christopher J. Williams,et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix , 2019, Acta crystallographica. Section D, Structural biology.
[33] David J. Fleet,et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.
[34] Marcus A. Brubaker,et al. Alignment of cryo-EM movies of individual particles by optimization of image translations. , 2014, Journal of structural biology.
[35] G. A. Lazar,et al. Enhanced antibody half-life improves in vivo activity , 2010, Nature Biotechnology.
[36] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.